Islet Co-Expression of CD133 and ABCB5 in Human Retinoblastoma Specimens.

Background: The role of CD133 und ABCB5 is discussed in treatment resistance in several types of cancer. The objective of this study was to evaluate whether CD133 ⁺ /ABCB5 ⁺ colocalization differs in untreated, in beam radiation treated, and in chemotherapy treated retinoblastoma specimens. Additionally, CD133, ABCB5, sphingosine kinase 1, and sphingosine kinase 2 gene expression was analyzed in WERI-RB1 (WERI RB1) and etoposide-resistant WERI RB1 subclones (WERI ETOR).
Methods: Active human untreated retinoblastoma specimens (n = 12), active human retinoblastoma specimens pretreated with beam radiation before enucleation (n = 8), and active human retinoblastoma specimens pretreated with chemotherapy before enucleation (n = 7) were investigated for localization and expression of CD133 and ABCB5 by immunohistochemistry. Only specimens with IIRC D, but not E, were included in this study. Furthermore, WERI RB1 and WERI ETOR cell lines were analyzed for CD133, ABCB5, sphingosine kinase 1, and sphingosine kinase 2 by the real-time polymerase chain reaction (RT-PCR).
Results: Immunohistochemical analysis revealed the same amount of CD133 ⁺ /ABCB5 ⁺ colocalization islets in untreated and treated human retinoblastoma specimens. Quantitative RT-PCR analysis showed a statistically significant upregulation of CD133 in WERI ETOR (p = 0.002). No ABCB5 expression was detected in WERI RB1 and WERI ETOR. On the other hand, SPHK1 (p = 0.0027) and SPHK2 (p = 0.017) showed significant downregulation in WERI ETOR compared to WERI RB1.
Conclusions: CD133 ⁺ /ABCB5 ⁺ co-localization islets were noted in untreated and treated human retinoblastoma specimens. Therefore, we assume that CD133 ⁺ /ABCB5 ⁺ islets might play a role in retinoblastoma genesis, but not in retinoblastoma treatment resistance.
Competing Interests: The authors declare that they have no conflict of interest.
(Thieme. All rights reserved.)